ReviewJournal of cellular and molecular medicine2021
Faecal microbial biomarkers in early diagnosis of colorectal cancer.
Review in Journal of cellular and molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Gut microbiome biomarkers for colorectal cancer detection: a systematic review highlighting age as a key confounder.Frontiers in oncology · 2026Pooled it
- Clinical applications of gut microbiome for non-invasive diagnosis of colorectal neoplasia.Journal of gastroenterology · 2026Article
- Review
- Article
- Engineering extracellular vesicles for inflammatory bowel disease and colitis-associated colorectal cancer: from therapeutic innovation to clinical translation.Frontiers in immunology · 2026Review
- Dysbiosis and colorectal cancer: conducive factors, biological and molecular role, and therapeutic prospectives.Exploration of targeted anti-tumor therapy · 2025Review
- Intestinal microbiota as biomarkers for different colorectal lesions based on colorectal cancer screening participants in community.Frontiers in microbiology · 2025Article
- Gut dysbiosis in cancer immunotherapy: microbiota-mediated resistance and emerging treatments.Frontiers in immunology · 2025Review
- Unveiling the overlooked fungi: the vital of gut fungi in inflammatory bowel disease and colorectal cancer.Gut pathogens · 2024Review
- Interaction of human gut microbiota and local immune system in progression of colorectal adenoma (MIMICA-1): a protocol for a prospective, observational cohort study.Frontiers in oncology · 2024Article
- From microbes to medicine: harnessing the gut microbiota to combat prostate cancer.Microbial cell (Graz, Austria) · 2024Article
- Metagenomic analysis of fecal samples in colorectal cancer Egyptians patients post colectomy: A pilot study.AIMS microbiology · 2024Article
- Wavelet scattering networks in deep learning for discovering protein markers in a cohort of Swedish rectal cancer patients.Cancer medicine · 2023Article
- Impact of Sustained Fructose Consumption on Gastrointestinal Function and Health inJournal of agricultural and food chemistry · 2023Article
- Progress and Perspectives in Colon Cancer Pathology, Diagnosis, and Treatments.Diseases (Basel, Switzerland) · 2023Review
- The Role of Bacteriophages in the Gut Microbiota: Implications for Human Health.Pharmaceutics · 2023Review
- Multi-omics analysis of fecal samples in colorectal cancer Egyptians patients: a pilot study.BMC microbiology · 2023Article
- Fecal microbial biomarkers combined with multi-target stool DNA test improve diagnostic accuracy for colorectal cancer.World journal of gastrointestinal oncology · 2023Article
- Fecal Microbiota and Associated Volatile Organic Compounds Distinguishing No-Adenoma from High-Risk Colon Adenoma Adults.Metabolites · 2023Article
- Interleukins (Cytokines) as Biomarkers in Colorectal Cancer: Progression, Detection, and Monitoring.Journal of clinical medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is ranked as the second most common cause of cancer deaths and the third most common cancer globally. It has been described as a 'silent disease' which is often easily treatable if detected early-before progression to carcinoma. Colonoscopy, which is the gold standard for diagnosis is not only expensive but is also an invasive diagnostic procedure, thus, effective and non-invasive diagnostic methods are urgently needed. Unfortunately, the current methods are not sensitive and specific enough in detecting adenomas and early colorectal neoplasia, hampering treatment and consequently, survival rates. Studies have shown that imbalances in such a relationship which renders the gut microbiota in a dysbiotic state are implicated in the development of adenomas ultimately resulting in CRC. The differences found in the makeup and diversity of the gut microbiota of healthy individuals relative to CRC patients have in recent times gained attention as potential biomarkers in early non-invasive diagnosis of CRC, with promising sensitivity, specificity and even cost-effectiveness. This review summarizes recent studies in the application of these microbiota biomarkers in early CRC diagnosis, limitations encountered in the area of the faecal microbiota studies as biomarkers for CRC, and future research exploits that address these limitations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.